{"count":13,"docs":"https://aiswingx.com/docs","items":[{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/Revenues","change":0.10160150424690398,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Revenue","label_en":"Revenue","label_ko":"\ub9e4\ucd9c","period_type":"duration","xbrl_tag":"Revenues"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/Revenues","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-47","unit":"USD","value":16990000000.0,"xbrl_fact_id":"f-47"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-48","unit":"USD","value":15423000000.0,"xbrl_fact_id":"f-48"}],"statement":"AbbVie Inc. (ABBV) reported Revenue of USD 16,990,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/Revenues","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-47"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/OperatingIncomeLoss","change":0.31426236207601144,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Operating income","label_en":"Operating income","label_ko":"\uc601\uc5c5\uc774\uc775","period_type":"duration","xbrl_tag":"OperatingIncomeLoss"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/OperatingIncomeLoss","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-75","unit":"USD","value":6432000000.0,"xbrl_fact_id":"f-75"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-76","unit":"USD","value":4894000000.0,"xbrl_fact_id":"f-76"}],"statement":"AbbVie Inc. (ABBV) reported Operating income of USD 6,432,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/OperatingIncomeLoss","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-75"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/NetIncomeLoss","change":2.85181236673774,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Net income","label_en":"Net income","label_ko":"\uc21c\uc774\uc775","period_type":"duration","xbrl_tag":"NetIncomeLoss"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/NetIncomeLoss","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-103","unit":"USD","value":3613000000.0,"xbrl_fact_id":"f-103"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-104","unit":"USD","value":938000000.0,"xbrl_fact_id":"f-104"}],"statement":"AbbVie Inc. (ABBV) reported Net income of USD 3,613,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/NetIncomeLoss","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-103"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/IncomeTaxExpenseBenefit","change":0.0799347471451876,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Income tax","label_en":"Income tax","label_ko":"\ubc95\uc778\uc138","period_type":"duration","xbrl_tag":"IncomeTaxExpenseBenefit"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/IncomeTaxExpenseBenefit","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-91","unit":"USD","value":662000000.0,"xbrl_fact_id":"f-91"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-92","unit":"USD","value":613000000.0,"xbrl_fact_id":"f-92"}],"statement":"AbbVie Inc. (ABBV) reported Income tax of USD 662,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/IncomeTaxExpenseBenefit","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-91"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/ShareBasedCompensation","change":0.035653650254668934,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Stock-based compensation","label_en":"Stock-based compensation","label_ko":"\uc8fc\uc2dd\ubcf4\uc0c1","period_type":"duration","xbrl_tag":"ShareBasedCompensation"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/ShareBasedCompensation","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-491","unit":"USD","value":610000000.0,"xbrl_fact_id":"f-491"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-492","unit":"USD","value":589000000.0,"xbrl_fact_id":"f-492"}],"statement":"AbbVie Inc. (ABBV) reported Stock-based compensation of USD 610,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/ShareBasedCompensation","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-491"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/NetCashProvidedByUsedInOperatingActivities","change":0.07027106658809665,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Operating cash flow","label_en":"Operating cash flow","label_ko":"\uc601\uc5c5\ud65c\ub3d9 \ud604\uae08\ud750\ub984","period_type":"duration","xbrl_tag":"NetCashProvidedByUsedInOperatingActivities"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/NetCashProvidedByUsedInOperatingActivities","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-509","unit":"USD","value":7265000000.0,"xbrl_fact_id":"f-509"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-510","unit":"USD","value":6788000000.0,"xbrl_fact_id":"f-510"}],"statement":"AbbVie Inc. (ABBV) reported Operating cash flow of USD 7,265,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/NetCashProvidedByUsedInOperatingActivities","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-509"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/PaymentsToAcquirePropertyPlantAndEquipment","change":0.16468253968253968,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Capex","label_en":"Capex","label_ko":"\uc124\ube44\ud22c\uc790","period_type":"duration","xbrl_tag":"PaymentsToAcquirePropertyPlantAndEquipment"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/PaymentsToAcquirePropertyPlantAndEquipment","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-515","unit":"USD","value":587000000.0,"xbrl_fact_id":"f-515"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-516","unit":"USD","value":504000000.0,"xbrl_fact_id":"f-516"}],"statement":"AbbVie Inc. (ABBV) reported Capex of USD 587,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/PaymentsToAcquirePropertyPlantAndEquipment","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-515"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/PaymentsForRepurchaseOfCommonStock","change":0.539568345323741,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Buybacks","label_en":"Buybacks","label_ko":"\uc790\uc0ac\uc8fc \ub9e4\uc785","period_type":"duration","xbrl_tag":"PaymentsForRepurchaseOfCommonStock"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/PaymentsForRepurchaseOfCommonStock","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-533","unit":"USD","value":1498000000.0,"xbrl_fact_id":"f-533"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-534","unit":"USD","value":973000000.0,"xbrl_fact_id":"f-534"}],"statement":"AbbVie Inc. (ABBV) reported Buybacks of USD 1,498,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/PaymentsForRepurchaseOfCommonStock","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-533"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/AccountsReceivableNetCurrent","change":0.09810151719755342,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Accounts receivable","label_en":"Accounts receivable","label_ko":"\ub9e4\ucd9c\ucc44\uad8c","period_type":"instant","xbrl_tag":"AccountsReceivableNetCurrent"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/AccountsReceivableNetCurrent","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-177","unit":"USD","value":13824000000.0,"xbrl_fact_id":"f-177"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-178","unit":"USD","value":12589000000.0,"xbrl_fact_id":"f-178"}],"statement":"AbbVie Inc. (ABBV) reported Accounts receivable of USD 13,824,000,000 as of 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/AccountsReceivableNetCurrent","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-177"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/InventoryNet","change":0.03554837406584528,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Inventory","label_en":"Inventory","label_ko":"\uc7ac\uace0","period_type":"instant","xbrl_tag":"InventoryNet"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/InventoryNet","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-179","unit":"USD","value":5127000000.0,"xbrl_fact_id":"f-179"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-180","unit":"USD","value":4951000000.0,"xbrl_fact_id":"f-180"}],"statement":"AbbVie Inc. (ABBV) reported Inventory of USD 5,127,000,000 as of 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/InventoryNet","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-179"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/CashAndCashEquivalentsAtCarryingValue","change":0.2562631478294129,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Cash","label_en":"Cash","label_ko":"\ud604\uae08","period_type":"instant","xbrl_tag":"CashAndCashEquivalentsAtCarryingValue"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/CashAndCashEquivalentsAtCarryingValue","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-175","unit":"USD","value":6569000000.0,"xbrl_fact_id":"f-175"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-176","unit":"USD","value":5229000000.0,"xbrl_fact_id":"f-176"}],"statement":"AbbVie Inc. (ABBV) reported Cash of USD 6,569,000,000 as of 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/CashAndCashEquivalentsAtCarryingValue","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-175"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/Assets","change":0.008621976709465512,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Total assets","label_en":"Total assets","label_ko":"\ucd1d\uc790\uc0b0","period_type":"instant","xbrl_tag":"Assets"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/Assets","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-195","unit":"USD","value":135115000000.0,"xbrl_fact_id":"f-195"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-196","unit":"USD","value":133960000000.0,"xbrl_fact_id":"f-196"}],"statement":"AbbVie Inc. (ABBV) reported Total assets of USD 135,115,000,000 as of 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/Assets","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-195"},{"accession":"0001551152-26-000026","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001551152-26-000026/StockholdersEquity","change":-0.8149847094801224,"cik":1551152,"company":"AbbVie Inc.","concept":{"label":"Total equity","label_en":"Total equity","label_ko":"\uc790\uae30\uc790\ubcf8","period_type":"instant","xbrl_tag":"StockholdersEquity"},"filed_at":"2026-08-03","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm","filing_url":"https://aiswingx.com/f/0001551152-26-000026","form":"10-Q","id":"0001551152-26-000026/StockholdersEquity","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-231","unit":"USD","value":-5935000000.0,"xbrl_fact_id":"f-231"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-232","unit":"USD","value":-3270000000.0,"xbrl_fact_id":"f-232"}],"statement":"AbbVie Inc. (ABBV) reported Total equity of USD -5,935,000,000 as of 2026-06-30 in its 10-Q (accession 0001551152-26-000026, filed 2026-08-03).","ticker":"ABBV","url":"https://aiswingx.com/n/0001551152-26-000026/StockholdersEquity","verify_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm#f-231"}],"limit":100,"note":"Inline XBRL facts as filed with the SEC, each with a permanent citation URL and a deep link to the figure in the filing document.","offset":0,"total":13}